It has been reported that up to 33% of hospitalized patients with COVID-19 have ARDS, 75 to 92% of patients admitted to the intensive care unit with COVID-19 have ARDS.

Source: https://seekingalpha.com/article/4626926-veru-inc-veru-q2-2023-earnings-call-transcript?source=feed_all_articles

It has been reported that up to 33% of hospitalized patients with COVID-19 have ARDS, 75 to 92% of patients admitted to the intensive care unit with COVID-19 have ARDS.

Source: https://seekingalpha.com/article/4626926-veru-inc-veru-q2-2023-earnings-call-transcript?source=feed_all_articles

Our data support the strategy of early combined use the ECMO to treat severe ARDS for acute respiratory distress syndrome and refractory lung failure and is a prime example of our hit early hit heart treatment philosophy.

Source: https://seekingalpha.com/article/4622483-cytosorbents-corporation-ctso-q2-2023-results-earnings-conference-call?source=feed_all_articles

Some individuals infected with the Nipah virus may also experience acute respiratory distress syndrome (ARDS).

Source: https://www.chiangraitimes.com/news/india-shutters-schools-offices-and-public-transport-over-nipah-virus/?utm_source=rss&utm_medium=rss&utm_campaign=india-shutters-schools-offices-and-public-transport-over-nipah-virus

The new Optiflow+ nasal high flow treatment device from Fisher & Paykel Healthcare Limited is intended to offer respiratory assistance to patients suffering from ARDS and other respiratory disorders.

Source: https://forextv.com/top-news/global-acute-respiratory-distress-syndrome-devices-market-is-anticipated-to-reach-us-651-6-million-by-2031-garnering-a-7-8-cagr-tmr-report/